相关实验视频

Updated: Jul 28, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

在卵巢癌中使用PARP抑制剂:一篇评论

David M O'Malley¹, Thomas C Krivak², Nashwa Kabil³

¹Division of Gynecology Oncology, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, OH, USA. David.O'Malley@osumc.edu.

Targeted oncology

|June 2, 2023

概括

聚基酶 (PARP) 抑制剂正在改变卵巢癌的治疗方法. 这些药物,包括olaparib,niraparib和rucaparib,作为维持疗法有效,改善了患者的治疗结果.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

聚ADP-ribose) 聚合酶 (PARP) 抑制剂 (PARPis) 已经显著推进了卵巢癌 (OC) 治疗.
该审查侧重于olaparib,niraparib和rucaparib,特别是它们在美国作为维持疗法的使用.

研究的目的:

在OC管理中提供PARPis的全面概述.
讨论PARPis作为维持疗法的作用,包括一线和后来的设置.
强调生物标志物测试对于治疗选择的重要性.

主要方法:

对临床试验数据和现实世界的证据进行叙述性审查.
在卵巢癌患者中分析PARPis (olaparib, niraparib, rucaparib) 的疗效和安全性.
专注于新诊断和复发情形中的维持治疗策略.

主要成果:

奥拉帕里布,尼拉帕里布和鲁卡帕里布已被批准在美国作为一线维护单一疗法.
组合疗法 (olaparib加贝瓦西祖马布) 在HRD阳性高级OC患者中显示出益处.
PARPis作为二线或后续维护对敏感性复发性OC的有效.
一般来说,PARP的耐受性很好,可控的不良事件并没有对生活质量产生负面影响.

结论:

PARP 抑制剂是卵巢癌治疗的基石,特别是作为维持疗法.
生物标志物测试对于确定谁将从PARPi治疗中获益最多的患者至关重要.
对新型组合的持续研究,如PARPis与免疫检查点抑制剂,对未来的OC治疗策略有前途.

更多相关视频

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...